When do you use high-dose IL-2 for metastatic renal cell carcinoma?

In general, as an academic investigator, I always prefer clinical trials over standard of care. However, most of the front line registration trials in mRCC with immunotherapy have recently completed accrual, with results currently awaited. I continue to offer the option of high dose Interleukin-2 (H...